We've found
8,177
archived clinical trials in
Orthopedic
We've found
8,177
archived clinical trials in
Orthopedic
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Updated: 12/31/1969
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)